John Reynolds, MD
Hematology & Oncology · Bismarck, NDNPI 1417027988
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,431 of the $1,611 with a category attached, or 88.8%. 17 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 25.0% of the total. Reporting peaked in 2023 at $619 and has fallen 83.6% since, to $101 in 2025.
Across 31 payments — averaging $51.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$403
- Bristol Myers Squibb$250
- Myriad Genetic Laboratories, Inc.$142
- Johnson & Johnson$116
- Eisai Inc.$111
- Takeda Pharmaceuticals U.S.A., Inc.$98
- plus $490 from 11 others
Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1K
What the payments were for
- Food & beverage$1,43189%
- Education$18011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 6 | $403 |
| Bristol Myers Squibb | 3 | $250 |
| Myriad Genetic Laboratories, Inc. | 3 | $142 |
| Johnson & Johnson | 2 | $116 |
| Eisai Inc. | 1 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $98 |
| Myovant Sciences Inc. | 1 | $95 |
| AstraZeneca | 3 | $95 |
| Seagen Inc. | 2 | $68 |
| AVEO Pharmaceuticals, Inc. | 1 | $58 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $55 |
| CTI Biopharma Corp. | 1 | $34 |
| Novartis | 1 | $24 |
| Mylan Institutional Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Servier Pharmaceuticals LLC | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,611 in reported general payments places this provider in the 70th percentile of 35 hematology & oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Bismarck
- Peter KurnialiBismarck$8K
- Matthew McGeeBismarck$3K
- Thandiwe GrayBismarck$2K
- Stewart SharpBismarck$2K
- Sagar RakshitBismarck$2K
- Alexander JohnsonBismarck$1K
- Edward WosBismarck$1K
- Aaron LuebkeBismarck$829
- David Oladele-BankoleBismarck$16
- Baruti SerabeBismarck$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.